AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis

AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis

Shots:

  • The CHMP positive opinion is based on P-III SELECT program including SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY assessing Rinvoq in 4,400+ patients with mod. to sev. active RA
  • In P-III studies, Rinvoq improved signs and symptoms of RA, inhibited radiographic progression and improved physical function, both as a monothx. and in combination with conventional synthetic DMARDs
  • Rinvoq is a selective and reversible JAK inhibitor, currently under review with health authorities globally to treat mod. to sev. active RA and being evaluated in P-III studies for multiple immune-mediated inflammatory diseases

Click here to­ read full press release/ article | Ref: AbbVie | Image: Supply Chain Asia